UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) ~~May~~July 1512, 2023

ALLIED ~~HEALTHCARE~~ HEALTHCARE PRODUCTS, INC. ~~(Exact name of Company as specified in its charter)~~

(Exact name of Company as specified in its charter)

Delaware	0-19266	25-1370721
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

~~1720~~55 ~~Sublette~~Monroe ~~Avenue,~~ St. ~~Louis~~Suite 2350, ~~Missouri~~Chicago, IL (Address of principal executive offices) ~~63110~~60603 (Zip Code)

Company’s telephone number, including area code (~~314~~312) ~~771~~254-~~2400~~0880 Not applicable (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the Company is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company ¨

If an emerging growth company, indicate by check mark if the Company has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
Common Stock, $.01	AHPIQ	OTC

Item 21.0203 ~~Results~~Bankruptcy ofor ~~Operations and Financial Condition~~Receivership.

OnItem ~~May 12, 2023, Allied Healthcare Products, Inc~~2. ~~(the~~01 ~~“Company”~~Completion ~~or “Allied”) filed Form 12b-25 Notification~~ of ~~Inability~~Acquisition toor ~~Timely~~Disposition ~~File its Quarterly Report on Form 10-Q for the quarter ended March 31, 2023. In the form 12b-25, Allied disclosed the following information regarding the results~~ of ~~operations~~ ~~and financial condition of the Company:~~Assets.

~~The~~As previously reported, on May 7, 2023, Allied Healthcare Products, Inc. (the “Company”) ~~experienced~~entered into a ~~loss~~stalking ofhorse ~~$2.2~~asset ~~million~~purchase agreement (the “STL Purchase ~~before~~Agreement”) ~~taxes~~with Allied Medical, LLC (“Purchaser”), for the ~~quarter,~~sale ~~compared~~of certain assets related to athe ~~loss~~Company’s ofbusiness operated ~~$1.3~~at ~~million~~the ~~before~~Company’s ~~taxes~~St. ~~for~~Louis Facility (the ~~same~~“STL ~~period~~Assets”) ofto ~~fiscal~~Purchaser ~~year~~as ~~2022.~~described ~~For~~in the ~~nine~~STL ~~months~~Purchase Agreement ~~ended~~(the ~~March~~“STL 31Sale”), ~~2023~~and ~~the~~a ~~Company~~stalking ~~experienced~~horse aasset ~~loss~~purchase ofagreement ~~$4.8~~(the ~~million~~“NY ~~before~~Purchase ~~taxes~~Agreement”) with Purchaser, for ~~compared~~the sale of certain assets related to ~~$3.4~~the ~~million~~Company’s ~~before~~business ~~taxes~~operated ~~for~~at the ~~same~~Company’s ~~period~~New York Facility (the “NY Assets”) to Purchaser as described in ~~fiscal~~the ~~year~~NY ~~2022~~Purchase Agreement (the “NY Sale”).

~~Net~~As ~~sales~~previously ~~for~~disclosed, on May 8, 2023 (the “Petition ~~quarter~~Date”), ofthe $5Company filed a voluntary petition (Case No.0 23-41607) ~~million~~(the ~~were~~“Chapter 11 Case”) for ~~$1.9~~relief ~~million~~under orChapter ~~27.5%~~11 ~~lower~~of ~~than~~title 11 of the ~~comparable~~United ~~quarter~~States Code (the “Bankruptcy Code”) in ~~fiscal~~the ~~2022.~~United ~~Domestically,~~States ~~sales~~Bankruptcy ~~decreased~~Court for bythe ~~$1.3~~Eastern ~~million~~District ~~while~~of ~~international sales,~~Missouri ~~which~~(the ~~represented~~“Bankruptcy 23Court”).5% Each of the ~~quarter’s~~STL ~~sales,~~Sale ~~were~~and ~~$0.6~~the ~~million~~proposed ~~lower.~~NY ~~Sales~~Sale ~~for~~was ~~the~~conducted through ~~quarter~~a ~~continued~~Bankruptcy Court-supervised process pursuant to beBankruptcy ~~negatively~~Court-approved bidding procedures and was subject to the approval ~~impacted~~of bythe ~~delays~~Bankruptcy inCourt. ~~obtaining~~The ~~inputs,~~Bankruptcy ~~production~~Court ~~delays,~~granted its approval to the STL Sale and athe ~~staffing~~NY ~~shortage~~Sale in ~~our~~orders ~~manufacturing~~granted ~~operation~~on June 30, 2023.

~~Net~~On ~~sales~~July 12, ~~for~~2023, the ~~nine~~Company ~~months~~and ~~ended~~the ~~March 31,~~Purchaser ~~2023~~consummated each of ~~$16.4~~the ~~million~~STL ~~were~~Sale ~~$4.6~~and ~~million~~the orNY 21Sale.9% ~~lower~~The ~~than~~aggregate ~~the~~final ~~same~~purchase ~~period~~price inof ~~fiscal~~the ~~2022.~~STL ~~Domestically,~~Assets ~~sales~~and ~~decreased~~NY byAssets, ~~$3.6~~after ~~million,~~all adjustments ~~while~~and ~~international~~reimbursements ~~sales,~~contemplated ~~which~~in ~~represented~~the ~~23.2%~~STL ofPurchase ~~the~~Agreement ~~period~~and ~~sales,~~NY ~~were~~Purchase ~~$1.0~~Agreement ~~million~~was ~~lower~~$8,988,974.

~~During~~The Chapter 11 Case remains pending. The full extent of the ~~nine~~Company’s ~~months~~liabilities ~~ended~~is ~~March~~not 31currently known, ~~2023~~and the Company ~~used~~cannot ~~$1.5~~give ~~million~~any assurance that holders of ~~cash~~the inCompany’s common ~~operating~~stock ~~activities~~will receive any payment or other distribution on account of those shares following the Chapter 11 Case.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	~~ALLIED HEALTHCARE PRODUCTS, INC.~~	ALLIED HEALTHCARE PRODUCTS, INC.
Date: May 15, 2023	By:	/s/ Daniel C. Dunn
Date: July 18, 2023		By:	/s/ Akash Amin
		Daniel C. Dunn
			Akash Amin
		Chief Financial Officer
			President and Chief Restructuring Officer

Filing Compare · ALLIED HEALTHCARE PRODUCTS INC